Industries > Pharma > Organ Transplant Rejection Medications Market Report 2021-2031
Organ Transplant Rejection Medications Market Report 2021-2031
By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitors, Antibodies, Steroids, and Others), By Transplant Type (Kidney Transplant, Bone Marrow Transplant, Liver Transplant, Heart Transplant, Lung Transplant, and Other Transplants), By End User (Hospitals, Organ Transplant Centers, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis
Organ Transplant Rejection Medications Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Organ Transplant Rejection Medications is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 190+ page report provides 80+ tables and 30+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Organ Transplant Rejection Medications Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Organ Transplant Rejection Medications Market By Drug Class
• Calcineurin Inhibitors
• Antiproliferative Agents
• mTOR Inhibitors
• Antibodies
• Steroids
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Organ Transplant Rejection Medications Market By Transplant Type
• Kidney Transplant
• Bone Marrow Transplant
• Liver Transplant
• Heart Transplant
• Lung Transplant
• Other Transplants
• Revenue and growth forecasts from 2021 to 2031 for the Global Organ Transplant Rejection Medications Market By End User
• Hospitals
• Organ Transplant Centers
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Organ Transplant Rejection Medications Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Organ Transplant Rejection Medications Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Organ Transplant Rejection Medications Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Organ Transplant Rejection Medications Market report helps you
In summary, our 190+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Organ Transplant Rejection Medications Market, with forecasts for each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Organ Transplant Rejection Medications market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Organ Transplant Rejection Medications Market. Some of the company’s profiled in this report include
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Astellas Pharma, Inc.
• Pfizer, Inc.
• AbbVie, Inc.
• Allergan plc.
• Bristol-Myers Squibb Company (BMS)
• Sanofi
• Mylan Laboratories, Inc.
• GlaxoSmithKline plc
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Organ Transplant Rejection Medications Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Organ Transplant Rejection Medications Market Report 2021-2031: By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitors, Antibodies, Steroids, and Others), By Transplant Type (Kidney Transplant, Bone Marrow Transplant, Liver Transplant, Heart Transplant, Lung Transplant, and Other Transplants), By End User (Hospitals, Organ Transplant Centers, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Organ Transplant Rejection Medications Market
2.1. Organ Transplant Rejection Medications Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Organ Transplant Rejection Medications Market Overview
3.1. Global Organ Transplant Rejection Medications Market Size and Forecast By Region
3.2. Global Organ Transplant Rejection Medications Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Growing organ transplantation and organ donation around the world
3.3.1.2. Increasing demand of for organ transplant rejection medications in emerging nations
3.3.1.3. Increasing research and development for organ transplant rejection medications
3.3.1.4. Increasing geriatric population around the world
3.3.1.5. Increasing strategic initiatives in organ transplant rejection medications market
3.3.2. Market Restraints
3.3.2.1. Stringent regulation
3.3.2.2. High cost of development
3.3.3. Opportunities
3.3.3.1. Increasing focus on healthcare infrastructure
3.3.3.2. Increasing therapeutic advancements in organ transplant rejection medications
3.3.4. Challenges
3.3.4.1. Availability of alternative methods
3.3.4.2. Side effects associated with the organ transplant rejection medications
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Organ Transplant Rejection Medications Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Calcineurin Inhibitors
4.1.1.1. Calcineurin Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.2. Antiproliferative Agents
4.1.2.1. Antiproliferative Agents market size and forecast, 2021-2031 (USD Million)
4.1.3. MTOR Inhibitors
4.1.3.1. MTOR Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.4. Antibodies
4.1.4.1. Antibodies market size and forecast, 2021-2031 (USD Million)
4.1.5. Steroids
4.1.5.1. Steroids market size and forecast, 2021-2031 (USD Million)
4.1.6. Lung Transplant
4.1.6.1. Lung Transplant market size and forecast, 2021-2031 (USD Million)
5. Global Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 By Transplant Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Kidney Transplant
5.1.1.1. Kidney Transplant market size and forecast, 2021-2031 (USD Million)
5.1.2. Bone Marrow Transplant
5.1.2.1. Bone Marrow Transplant market size and forecast, 2021-2031 (USD Million)
5.1.3. Lung Transplant
5.1.3.1. Lung Transplant market size and forecast, 2021-2031 (USD Million)
5.1.4. Heart Transplant
5.1.4.1. Heart Transplant market size and forecast, 2021-2031 (USD Million)
5.1.5. Lung Transplant
5.1.5.1. Lung Transplant market size and forecast, 2021-2031 (USD Million)
5.1.6. Other Transplants
5.1.6.1. Other Transplants market size and forecast, 2021-2031 (USD Million)
6. Global Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospitals
6.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
6.1.2. Organ Transplant Centers
6.1.2.1. Organ Transplant Centers market size and forecast, 2021-2031 (USD Million)
6.1.3. Specialty Clinics
6.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
6.1.4. Lung Transplant
6.1.4.1. Lung Transplant market size and forecast, 2021-2031 (USD Million)
7. Global Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Direct Tender
7.1.1.1. Direct Tender market size and forecast, 2021-2031 (USD Million)
7.1.2. Retail Sales
7.1.2.1. Retail Sales market size and forecast, 2021-2031 (USD Million)
8. North America Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. North America Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
8.2.1.1. XX Driving/Opportunity Factor
8.2.1.2. XX Driving/Opportunity Factor
8.3. North America Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
8.3.1.1. XX Driving/Opportunity Factor
8.3.1.2. XX Driving/Opportunity Factor
8.4. North America Organ Transplant Rejection Medications Market Size and Forecast By End-User
8.4.1.1. XX Driving/Opportunity Factor
8.4.1.2. XX Driving/Opportunity Factor
8.5. North America Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
8.5.1.1. XX Driving/Opportunity Factor
8.5.1.2. XX Driving/Opportunity Factor
8.6. U.S. Organ Transplant Rejection Medications Market
8.6.1.1. XX Driving/Opportunity Factor
8.6.1.2. XX Driving/Opportunity Factor
8.7. Canada Organ Transplant Rejection Medications Market
8.7.1.1. XX Driving/Opportunity Factor
8.7.1.2. XX Driving/Opportunity Factor
9. Europe Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Europe Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
9.2.1.1. XX Driving/Opportunity Factor
9.2.1.2. XX Driving/Opportunity Factor
9.3. Europe Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
9.3.1.1. XX Driving/Opportunity Factor
9.3.1.2. XX Driving/Opportunity Factor
9.4. Europe Organ Transplant Rejection Medications Market Size and Forecast By End-User
9.4.1.1. XX Driving/Opportunity Factor
9.4.1.2. XX Driving/Opportunity Factor
9.5. Europe Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
9.5.1.1. XX Driving/Opportunity Factor
9.5.1.2. XX Driving/Opportunity Factor
9.6. UK Organ Transplant Rejection Medications Market
9.6.1.1. XX Driving/Opportunity Factor
9.6.1.2. XX Driving/Opportunity Factor
9.7. Germany Organ Transplant Rejection Medications Market
9.7.1.1. XX Driving/Opportunity Factor
9.7.1.2. XX Driving/Opportunity Factor
9.8. France Organ Transplant Rejection Medications Market
9.8.1.1. XX Driving/Opportunity Factor
9.8.1.2. XX Driving/Opportunity Factor
9.9. Rest of Europe Organ Transplant Rejection Medications Market
9.9.1.1. XX Driving/Opportunity Factor
9.9.1.2. XX Driving/Opportunity Factor
10. Asia Pacific Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Asia-Pacific Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. Asia-Pacific Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. Asia-Pacific Organ Transplant Rejection Medications Market Size and Forecast By End-User
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. Asia-Pacific Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. China Organ Transplant Rejection Medications Market
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. India Organ Transplant Rejection Medications Market
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. Japan Organ Transplant Rejection Medications Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Rest of Asia Pacific Organ Transplant Rejection Medications Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Latin America Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Latin America Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Latin America Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Latin America Organ Transplant Rejection Medications Market Size and Forecast By End-User
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Latin America Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
11.6. Brazil Organ Transplant Rejection Medications Market
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Mexico Organ Transplant Rejection Medications Market
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. Rest of Latin America Organ Transplant Rejection Medications Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
12. MEA Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. MEA Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. MEA Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. MEA Organ Transplant Rejection Medications Market Size and Forecast By End-User
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. MEA Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. GCC Organ Transplant Rejection Medications Market
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. South Africa Organ Transplant Rejection Medications Market
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Rest of MEA Organ Transplant Rejection Medications Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
13. Companies in the Organ Transplant Rejection Medications Market
13.1. Novartis AG
13.1.1. Company Snapshot
13.1.2. Company Overview
13.1.3. Financial Performance (2015-2019)
13.1.3.1. Net Revenue
13.1.3.2. Gross Profit
13.1.3.3. Geographical Revenue, 2019
13.1.4. Product Offerings
13.1.5. Recent Initiatives (2017-2019)
13.2. F. Hoffmann-La Roche Ltd.
13.2.1. Company Snapshot
13.2.2. Company Overview
13.2.3. Financial Performance (2015-2019)
13.2.3.1. Net Revenue
13.2.3.2. Gross Profit
13.2.3.3. Geographical Revenue, 2019
13.2.4. Product Offerings
13.2.5. Recent Initiatives (2017-2019)
13.3. Astellas Pharma, Inc.
13.3.1. Company Snapshot
13.3.2. Company Overview
13.3.3. Financial Performance (2015-2019)
13.3.3.1. Net Revenue
13.3.3.2. Gross Profit
13.3.3.3. Geographical Revenue, 2019
13.3.4. Product Offerings
13.3.5. Recent Initiatives (2017-2019)
13.4. Pfizer, Inc.
13.4.1. Company Snapshot
13.4.2. Company Overview
13.4.3. Financial Performance (2015-2019)
13.4.3.1. Net Revenue
13.4.3.2. Gross Profit
13.4.3.3. Geographical Revenue, 2019
13.4.4. Product Offerings
13.4.5. Recent Initiatives (2017-2019)
13.5. AbbVie, Inc.
13.5.1. Company Snapshot
13.5.2. Company Overview
13.5.3. Financial Performance (2015-2019)
13.5.3.1. Net Revenue
13.5.3.2. Gross Profit
13.5.3.3. Geographical Revenue, 2019
13.5.4. Product Offerings
13.5.5. Recent Initiatives (2017-2019)
13.6. Allergan plc.
13.6.1. Company Snapshot
13.6.2. Company Overview
13.6.3. Financial Performance (2015-2019)
13.6.3.1. Net Revenue
13.6.3.2. Gross Profit
13.6.3.3. Geographical Revenue, 2019
13.6.4. Product Offerings
13.6.5. Recent Initiatives (2017-2019)
13.7. GlaxoSmithKline plc
13.7.1. Company Snapshot
13.7.2. Company Overview
13.7.3. Financial Performance (2015-2019)
13.7.3.1. Net Revenue
13.7.3.2. Gross Profit
13.7.3.3. Geographical Revenue, 2019
13.7.4. Product Offerings
13.7.5. Recent Initiatives (2017-2019)
13.8. Sanofi
13.8.1. Company Snapshot
13.8.2. Company Overview
13.8.3. Financial Performance (2015-2019)
13.8.3.1. Net Revenue
13.8.3.2. Gross Profit
13.8.3.3. Geographical Revenue, 2019
13.8.4. Product Offerings
13.8.5. Recent Initiatives (2017-2019)
13.9. Mylan Laboratories, Inc.
13.9.1. Company Snapshot
13.9.2. Company Overview
13.9.3. Financial Performance (2015-2019)
13.9.3.1. Net Revenue
13.9.3.2. Gross Profit
13.9.3.3. Geographical Revenue, 2019
13.9.4. Product Offerings
13.9.5. Recent Initiatives (2017-2019)
13.10. GlaxoSmithKline plc
13.10.1. Company Snapshot
13.10.2. Company Overview
13.10.3. Financial Performance (2015-2019)
13.10.3.1. Net Revenue
13.10.3.2. Gross Profit
13.10.3.3. Geographical Revenue, 2019
13.10.4. Product Offerings
13.10.5. Recent Initiatives (2017-2019)
13.11. Other Notable Players
14. Conclusion
15. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Organ Transplant Rejection Medications Market Drivers & Restraints 2021
Table 7. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 153. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 196. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Leading 10 Organ Transplant Rejection Medications Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 302. Novartis AGProfile 2019 (CEO, HQ, Founded, Website)
Table 303. Novartis AG Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 304. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 305. F. Hoffmann-La Roche Ltd. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 306. Astellas Pharma, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 307. Astellas Pharma, Inc..Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 308. Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 309. Pfizer, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 310. AbbVie, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 311. AbbVie, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 312. Allergan plc. Profile 2019 (CEO, HQ, Founded, Website)
Table 313. Allergan plc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 314. GlaxoSmithKline plc Profile 2019 (CEO, HQ, Founded, Website)
Table 315. GlaxoSmithKline plc Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 316. Sanofi Profile 2019 (CEO, HQ, Founded, Website)
Table 317. Sanofi Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 318. Mylan Laboratories, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 319. Mylan Laboratories, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 320. GlaxoSmithKline plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 321. GlaxoSmithKline plc Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 322. Other Companies Involved in the Organ Transplant Rejection Medications Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Organ Transplant Rejection Medications Market Drivers & Restraints 2021
Figure 7. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 118. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 123. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 128. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 153. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 173. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 174. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 175. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 176. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 177. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 178. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 179. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 180. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 181. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 182. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 183. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 184. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 185. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 186. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 187. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 188. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 189. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 190. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 191. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 192. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 193. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 194. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 195. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 196. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 197. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 222. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Leading 10 Organ Transplant Rejection Medications Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Figure 302. Novartis AGProfile 2019 (CEO, HQ, Founded, Website)
Figure 303. Novartis AG Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 304. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Figure 305. F. Hoffmann-La Roche Ltd. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 306. Astellas Pharma, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 307. Astellas Pharma, Inc..Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 308. Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 309. Pfizer, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 310. AbbVie, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 311. AbbVie, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 312. Allergan plc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 313. Allergan plc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 314. GlaxoSmithKline plc Profile 2019 (CEO, HQ, Founded, Website)
Figure 315. GlaxoSmithKline plc Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 316. Sanofi Profile 2019 (CEO, HQ, Founded, Website)
Figure 317. Sanofi Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 318. Mylan Laboratories, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 319. Mylan Laboratories, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 320. GlaxoSmithKline plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 321. GlaxoSmithKline plc Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 322. Porter’s Five Force Analysis
Companies Mentioned
1. Paragonix Technologies
2. Astellas Pharma, Inc.
3. Transmedics
4. Shanghai Genext Medical Technology
5. Waters Medical Systems
6. Preservation Solutions
7. Carnamedica
8. Transplant Biomedicals
9. Organ Assist
10. Institut Georges Lopez
11. Global Transplant Solutions
12. Avionord
13. Organ Transplant Rejection Medications
14. Ebers
15. S.A.L.F.
16. Actelion
17. Affinium Pharmaceutical
18. AiCuris GmbH & Co. KG
19. Alcon
20. Alkem Laboratories
21. Allergan
22. Allied Pharma
23. Apotex
24. APP Pharmaceuticals
25. Aptalis Pharma
26. Aquapharm Biodiscovery
27. Cempra Pharmaceuticals
28. Cipla
29. Claris Lifesciences
30. Cornerstone Biopharma
31. Cornerstone Therapeutics
32. Corona Remedies
33. Eli Lilly
34. Gate Pharma
35. Gilead Sciences
36. GlaxoSmithKline (GSK)
37. Glenmark
38. GlycoVaxyn
39. Hetero
40. Hikma Farmaceutica
41. Hi-Tech Pharma
42. Hospira
43. Macleod Pharmaceuticals
44. Microlabs
45. Nalneva
46. Novartis
47. Novexel
48. Paratek Pharmaceuticals
49. Pfizer
50. Ranbaxy
51. Roche
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Organ Transplant Rejection Medications Market
2.1. Organ Transplant Rejection Medications Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Organ Transplant Rejection Medications Market Overview
3.1. Global Organ Transplant Rejection Medications Market Size and Forecast By Region
3.2. Global Organ Transplant Rejection Medications Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Growing organ transplantation and organ donation around the world
3.3.1.2. Increasing demand of for organ transplant rejection medications in emerging nations
3.3.1.3. Increasing research and development for organ transplant rejection medications
3.3.1.4. Increasing geriatric population around the world
3.3.1.5. Increasing strategic initiatives in organ transplant rejection medications market
3.3.2. Market Restraints
3.3.2.1. Stringent regulation
3.3.2.2. High cost of development
3.3.3. Opportunities
3.3.3.1. Increasing focus on healthcare infrastructure
3.3.3.2. Increasing therapeutic advancements in organ transplant rejection medications
3.3.4. Challenges
3.3.4.1. Availability of alternative methods
3.3.4.2. Side effects associated with the organ transplant rejection medications
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Organ Transplant Rejection Medications Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Calcineurin Inhibitors
4.1.1.1. Calcineurin Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.2. Antiproliferative Agents
4.1.2.1. Antiproliferative Agents market size and forecast, 2021-2031 (USD Million)
4.1.3. MTOR Inhibitors
4.1.3.1. MTOR Inhibitors market size and forecast, 2021-2031 (USD Million)
4.1.4. Antibodies
4.1.4.1. Antibodies market size and forecast, 2021-2031 (USD Million)
4.1.5. Steroids
4.1.5.1. Steroids market size and forecast, 2021-2031 (USD Million)
4.1.6. Lung Transplant
4.1.6.1. Lung Transplant market size and forecast, 2021-2031 (USD Million)
5. Global Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 By Transplant Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Kidney Transplant
5.1.1.1. Kidney Transplant market size and forecast, 2021-2031 (USD Million)
5.1.2. Bone Marrow Transplant
5.1.2.1. Bone Marrow Transplant market size and forecast, 2021-2031 (USD Million)
5.1.3. Lung Transplant
5.1.3.1. Lung Transplant market size and forecast, 2021-2031 (USD Million)
5.1.4. Heart Transplant
5.1.4.1. Heart Transplant market size and forecast, 2021-2031 (USD Million)
5.1.5. Lung Transplant
5.1.5.1. Lung Transplant market size and forecast, 2021-2031 (USD Million)
5.1.6. Other Transplants
5.1.6.1. Other Transplants market size and forecast, 2021-2031 (USD Million)
6. Global Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospitals
6.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
6.1.2. Organ Transplant Centers
6.1.2.1. Organ Transplant Centers market size and forecast, 2021-2031 (USD Million)
6.1.3. Specialty Clinics
6.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
6.1.4. Lung Transplant
6.1.4.1. Lung Transplant market size and forecast, 2021-2031 (USD Million)
7. Global Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Direct Tender
7.1.1.1. Direct Tender market size and forecast, 2021-2031 (USD Million)
7.1.2. Retail Sales
7.1.2.1. Retail Sales market size and forecast, 2021-2031 (USD Million)
8. North America Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. North America Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
8.2.1.1. XX Driving/Opportunity Factor
8.2.1.2. XX Driving/Opportunity Factor
8.3. North America Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
8.3.1.1. XX Driving/Opportunity Factor
8.3.1.2. XX Driving/Opportunity Factor
8.4. North America Organ Transplant Rejection Medications Market Size and Forecast By End-User
8.4.1.1. XX Driving/Opportunity Factor
8.4.1.2. XX Driving/Opportunity Factor
8.5. North America Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
8.5.1.1. XX Driving/Opportunity Factor
8.5.1.2. XX Driving/Opportunity Factor
8.6. U.S. Organ Transplant Rejection Medications Market
8.6.1.1. XX Driving/Opportunity Factor
8.6.1.2. XX Driving/Opportunity Factor
8.7. Canada Organ Transplant Rejection Medications Market
8.7.1.1. XX Driving/Opportunity Factor
8.7.1.2. XX Driving/Opportunity Factor
9. Europe Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Europe Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
9.2.1.1. XX Driving/Opportunity Factor
9.2.1.2. XX Driving/Opportunity Factor
9.3. Europe Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
9.3.1.1. XX Driving/Opportunity Factor
9.3.1.2. XX Driving/Opportunity Factor
9.4. Europe Organ Transplant Rejection Medications Market Size and Forecast By End-User
9.4.1.1. XX Driving/Opportunity Factor
9.4.1.2. XX Driving/Opportunity Factor
9.5. Europe Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
9.5.1.1. XX Driving/Opportunity Factor
9.5.1.2. XX Driving/Opportunity Factor
9.6. UK Organ Transplant Rejection Medications Market
9.6.1.1. XX Driving/Opportunity Factor
9.6.1.2. XX Driving/Opportunity Factor
9.7. Germany Organ Transplant Rejection Medications Market
9.7.1.1. XX Driving/Opportunity Factor
9.7.1.2. XX Driving/Opportunity Factor
9.8. France Organ Transplant Rejection Medications Market
9.8.1.1. XX Driving/Opportunity Factor
9.8.1.2. XX Driving/Opportunity Factor
9.9. Rest of Europe Organ Transplant Rejection Medications Market
9.9.1.1. XX Driving/Opportunity Factor
9.9.1.2. XX Driving/Opportunity Factor
10. Asia Pacific Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Asia-Pacific Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. Asia-Pacific Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. Asia-Pacific Organ Transplant Rejection Medications Market Size and Forecast By End-User
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. Asia-Pacific Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. China Organ Transplant Rejection Medications Market
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. India Organ Transplant Rejection Medications Market
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. Japan Organ Transplant Rejection Medications Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Rest of Asia Pacific Organ Transplant Rejection Medications Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Latin America Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Latin America Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Latin America Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Latin America Organ Transplant Rejection Medications Market Size and Forecast By End-User
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Latin America Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
11.6. Brazil Organ Transplant Rejection Medications Market
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Mexico Organ Transplant Rejection Medications Market
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. Rest of Latin America Organ Transplant Rejection Medications Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
12. MEA Organ Transplant Rejection Medications Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. MEA Organ Transplant Rejection Medications Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. MEA Organ Transplant Rejection Medications Market Size and Forecast By Transplant Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. MEA Organ Transplant Rejection Medications Market Size and Forecast By End-User
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. MEA Organ Transplant Rejection Medications Market Size and Forecast By Distribution Channel
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. GCC Organ Transplant Rejection Medications Market
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. South Africa Organ Transplant Rejection Medications Market
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Rest of MEA Organ Transplant Rejection Medications Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
13. Companies in the Organ Transplant Rejection Medications Market
13.1. Novartis AG
13.1.1. Company Snapshot
13.1.2. Company Overview
13.1.3. Financial Performance (2015-2019)
13.1.3.1. Net Revenue
13.1.3.2. Gross Profit
13.1.3.3. Geographical Revenue, 2019
13.1.4. Product Offerings
13.1.5. Recent Initiatives (2017-2019)
13.2. F. Hoffmann-La Roche Ltd.
13.2.1. Company Snapshot
13.2.2. Company Overview
13.2.3. Financial Performance (2015-2019)
13.2.3.1. Net Revenue
13.2.3.2. Gross Profit
13.2.3.3. Geographical Revenue, 2019
13.2.4. Product Offerings
13.2.5. Recent Initiatives (2017-2019)
13.3. Astellas Pharma, Inc.
13.3.1. Company Snapshot
13.3.2. Company Overview
13.3.3. Financial Performance (2015-2019)
13.3.3.1. Net Revenue
13.3.3.2. Gross Profit
13.3.3.3. Geographical Revenue, 2019
13.3.4. Product Offerings
13.3.5. Recent Initiatives (2017-2019)
13.4. Pfizer, Inc.
13.4.1. Company Snapshot
13.4.2. Company Overview
13.4.3. Financial Performance (2015-2019)
13.4.3.1. Net Revenue
13.4.3.2. Gross Profit
13.4.3.3. Geographical Revenue, 2019
13.4.4. Product Offerings
13.4.5. Recent Initiatives (2017-2019)
13.5. AbbVie, Inc.
13.5.1. Company Snapshot
13.5.2. Company Overview
13.5.3. Financial Performance (2015-2019)
13.5.3.1. Net Revenue
13.5.3.2. Gross Profit
13.5.3.3. Geographical Revenue, 2019
13.5.4. Product Offerings
13.5.5. Recent Initiatives (2017-2019)
13.6. Allergan plc.
13.6.1. Company Snapshot
13.6.2. Company Overview
13.6.3. Financial Performance (2015-2019)
13.6.3.1. Net Revenue
13.6.3.2. Gross Profit
13.6.3.3. Geographical Revenue, 2019
13.6.4. Product Offerings
13.6.5. Recent Initiatives (2017-2019)
13.7. GlaxoSmithKline plc
13.7.1. Company Snapshot
13.7.2. Company Overview
13.7.3. Financial Performance (2015-2019)
13.7.3.1. Net Revenue
13.7.3.2. Gross Profit
13.7.3.3. Geographical Revenue, 2019
13.7.4. Product Offerings
13.7.5. Recent Initiatives (2017-2019)
13.8. Sanofi
13.8.1. Company Snapshot
13.8.2. Company Overview
13.8.3. Financial Performance (2015-2019)
13.8.3.1. Net Revenue
13.8.3.2. Gross Profit
13.8.3.3. Geographical Revenue, 2019
13.8.4. Product Offerings
13.8.5. Recent Initiatives (2017-2019)
13.9. Mylan Laboratories, Inc.
13.9.1. Company Snapshot
13.9.2. Company Overview
13.9.3. Financial Performance (2015-2019)
13.9.3.1. Net Revenue
13.9.3.2. Gross Profit
13.9.3.3. Geographical Revenue, 2019
13.9.4. Product Offerings
13.9.5. Recent Initiatives (2017-2019)
13.10. GlaxoSmithKline plc
13.10.1. Company Snapshot
13.10.2. Company Overview
13.10.3. Financial Performance (2015-2019)
13.10.3.1. Net Revenue
13.10.3.2. Gross Profit
13.10.3.3. Geographical Revenue, 2019
13.10.4. Product Offerings
13.10.5. Recent Initiatives (2017-2019)
13.11. Other Notable Players
14. Conclusion
15. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Organ Transplant Rejection Medications Market Drivers & Restraints 2021
Table 7. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 153. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 196. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Leading 10 Organ Transplant Rejection Medications Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 302. Novartis AGProfile 2019 (CEO, HQ, Founded, Website)
Table 303. Novartis AG Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 304. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 305. F. Hoffmann-La Roche Ltd. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 306. Astellas Pharma, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 307. Astellas Pharma, Inc..Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 308. Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 309. Pfizer, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 310. AbbVie, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 311. AbbVie, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 312. Allergan plc. Profile 2019 (CEO, HQ, Founded, Website)
Table 313. Allergan plc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 314. GlaxoSmithKline plc Profile 2019 (CEO, HQ, Founded, Website)
Table 315. GlaxoSmithKline plc Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 316. Sanofi Profile 2019 (CEO, HQ, Founded, Website)
Table 317. Sanofi Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 318. Mylan Laboratories, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 319. Mylan Laboratories, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 320. GlaxoSmithKline plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 321. GlaxoSmithKline plc Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Table 322. Other Companies Involved in the Organ Transplant Rejection Medications Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Organ Transplant Rejection Medications Market Drivers & Restraints 2021
Figure 7. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Calcineurin Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Antiproliferative Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. MTOR Inhibitors Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Steroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Kidney Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Bone Marrow Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Heart Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Other Transplants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Organ Transplant Centers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Lung Transplant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 118. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. North America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 123. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. North America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 128. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. North America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. North America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. North America Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. US Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Canada Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 153. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Europe Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Europe Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Europe Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Europe Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 173. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 174. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 175. Europe Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 176. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 177. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 178. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 179. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 180. UK Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 181. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 182. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 183. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 184. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 185. Germany Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 186. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 187. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 188. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 189. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 190. France Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 191. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 192. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 193. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 194. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 195. Rest of Europe Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 196. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 197. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. Asia Pacific Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Asia Pacific Organ Transplant Rejection Medications Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 222. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. China Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. India Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Japan Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. RoAPAC Organ Transplant Rejection Medications Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Middle East Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Middle East Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. Middle East Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Middle East Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Latin America Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Latin America Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Latin America Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Latin America Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Africa Organ Transplant Rejection Medications Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Africa Organ Transplant Rejection Medications Market Forecast By Transplant Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Africa Organ Transplant Rejection Medications Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Africa Organ Transplant Rejection Medications Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Leading 10 Organ Transplant Rejection Medications Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Figure 302. Novartis AGProfile 2019 (CEO, HQ, Founded, Website)
Figure 303. Novartis AG Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 304. F. Hoffmann-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Figure 305. F. Hoffmann-La Roche Ltd. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 306. Astellas Pharma, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 307. Astellas Pharma, Inc..Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 308. Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 309. Pfizer, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 310. AbbVie, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 311. AbbVie, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 312. Allergan plc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 313. Allergan plc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 314. GlaxoSmithKline plc Profile 2019 (CEO, HQ, Founded, Website)
Figure 315. GlaxoSmithKline plc Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 316. Sanofi Profile 2019 (CEO, HQ, Founded, Website)
Figure 317. Sanofi Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 318. Mylan Laboratories, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Figure 319. Mylan Laboratories, Inc. Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 320. GlaxoSmithKline plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Figure 321. GlaxoSmithKline plc Organ Transplant Rejection Medications Product Offering (Segment, Product Offerings)
Figure 322. Porter’s Five Force Analysis
Companies Mentioned
1. Paragonix Technologies
2. Astellas Pharma, Inc.
3. Transmedics
4. Shanghai Genext Medical Technology
5. Waters Medical Systems
6. Preservation Solutions
7. Carnamedica
8. Transplant Biomedicals
9. Organ Assist
10. Institut Georges Lopez
11. Global Transplant Solutions
12. Avionord
13. Organ Transplant Rejection Medications
14. Ebers
15. S.A.L.F.
16. Actelion
17. Affinium Pharmaceutical
18. AiCuris GmbH & Co. KG
19. Alcon
20. Alkem Laboratories
21. Allergan
22. Allied Pharma
23. Apotex
24. APP Pharmaceuticals
25. Aptalis Pharma
26. Aquapharm Biodiscovery
27. Cempra Pharmaceuticals
28. Cipla
29. Claris Lifesciences
30. Cornerstone Biopharma
31. Cornerstone Therapeutics
32. Corona Remedies
33. Eli Lilly
34. Gate Pharma
35. Gilead Sciences
36. GlaxoSmithKline (GSK)
37. Glenmark
38. GlycoVaxyn
39. Hetero
40. Hikma Farmaceutica
41. Hi-Tech Pharma
42. Hospira
43. Macleod Pharmaceuticals
44. Microlabs
45. Nalneva
46. Novartis
47. Novexel
48. Paratek Pharmaceuticals
49. Pfizer
50. Ranbaxy
51. Roche
Companies Profiled in the Report
1. Novartis AG
2. F. Hoffmann-La Roche Ltd.
3. Astellas Pharma, Inc.
4. Pfizer, Inc.
5. AbbVie, Inc.
6. Allergan plc.
7. Bristol-Myers Squibb Company (BMS)
8. Sanofi
9. Mylan Laboratories, Inc.
10. GlaxoSmithKline plc
List of Companies Mentioned in the Report:
1. Paragonix Technologies
2. XVIVO Perfusion AB
3. Transmedics
4. Shanghai Genext Medical Technology
5. Waters Medical Systems
6. Preservation Solutions
7. Carnamedica
8. Transplant Biomedicals
9. Organ Assist
10. Institut Georges Lopez
11. Global Transplant Solutions
12. Avionord
13. Organ Transplant Rejection Medications
14. Ebers
15. S.A.L.F.
16. Actelion
17. Affinium Pharmaceutical
18. AiCuris GmbH & Co. KG
19. Alcon
20. Alkem Laboratories
21. Allergan
22. Allied Pharma
23. Apotex
24. APP Pharmaceuticals
25. Aptalis Pharma
26. Aquapharm Biodiscovery
27. Cempra Pharmaceuticals
28. Cipla
29. Claris Lifesciences
30. Cornerstone Biopharma
31. Cornerstone Therapeutics
32. Corona Remedies
33. Eli Lilly
34. Gate Pharma
35. Gilead Sciences
36. GlaxoSmithKline (GSK)
37. Glenmark
38. GlycoVaxyn
39. Hetero
40. Hikma Farmaceutica
41. Hi-Tech Pharma
42. Hospira
43. Macleod Pharmaceuticals
44. Microlabs
45. Nalneva
46. Novartis
47. Novexel
48. Paratek Pharmaceuticals
49. Pfizer
50. Ranbaxy
51. Roche
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
1. Novartis AG
2. F. Hoffmann-La Roche Ltd.
3. Astellas Pharma, Inc.
4. Pfizer, Inc.
5. AbbVie, Inc.
6. Allergan plc.
7. Bristol-Myers Squibb Company (BMS)
8. Sanofi
9. Mylan Laboratories, Inc.
10. GlaxoSmithKline plc
List of Companies Mentioned in the Report:
1. Paragonix Technologies
2. XVIVO Perfusion AB
3. Transmedics
4. Shanghai Genext Medical Technology
5. Waters Medical Systems
6. Preservation Solutions
7. Carnamedica
8. Transplant Biomedicals
9. Organ Assist
10. Institut Georges Lopez
11. Global Transplant Solutions
12. Avionord
13. Organ Transplant Rejection Medications
14. Ebers
15. S.A.L.F.
16. Actelion
17. Affinium Pharmaceutical
18. AiCuris GmbH & Co. KG
19. Alcon
20. Alkem Laboratories
21. Allergan
22. Allied Pharma
23. Apotex
24. APP Pharmaceuticals
25. Aptalis Pharma
26. Aquapharm Biodiscovery
27. Cempra Pharmaceuticals
28. Cipla
29. Claris Lifesciences
30. Cornerstone Biopharma
31. Cornerstone Therapeutics
32. Corona Remedies
33. Eli Lilly
34. Gate Pharma
35. Gilead Sciences
36. GlaxoSmithKline (GSK)
37. Glenmark
38. GlycoVaxyn
39. Hetero
40. Hikma Farmaceutica
41. Hi-Tech Pharma
42. Hospira
43. Macleod Pharmaceuticals
44. Microlabs
45. Nalneva
46. Novartis
47. Novexel
48. Paratek Pharmaceuticals
49. Pfizer
50. Ranbaxy
51. Roche
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
Download sample pages
Complete the form below to download your free sample pages for Organ Transplant Rejection Medications Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Organ Transplant Rejection Medications Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023
